Kobayashi, Masatake
Girerd, Nicolas
Duarte, Kevin
Preud’homme, Gregoire
Pitt, Bertram
Rossignol, Patrick
Funding for this research was provided by:
National Heart, Lung, and Blood Institute (HHSN268200425207C)
Agence Nationale de la Recherche (ANR-15-RHUS-0004, ANR-15-IDEX-04-LUE, ANR-15-CE14-0032-01, ANR-16-ECVD-0002-02)
Article History
Received: 29 January 2020
Accepted: 24 March 2020
First Online: 6 April 2020
Compliance with ethical standards
:
: P.R. reports grants and personal fees from AstraZeneca, grants and personal fees from Bayer, grants and personal fees from CVRx, personal fees from Fresenius, grants and personal fees from Novartis, personal fees from Grunenthal, personal fees from Servier, personal fees from Stealth Peptides, personal fees from Vifor Fresenius Medical Care Renal Pharma, personal fees from Idorsia, personal fees from NovoNordisk, personal fees from Ablative Solutions, personal fees from G3P, personal fees from Corvidia, personal fees from Relypsa, outside the submitted work; and Cofounder: CardioRenal, a company developing a telemonitoring loop in heart failure (including potassium measurements). B.P. reports personal fees (consulting) from Bayer, KBP Pharmaceuticals, AstraZeneca, Relypsa/Vifor, Sanofi, sc Pharmaceuticals, Sarfez pharmaceuticals, Stealth Peptides, Cereno Scientific, SQinnovations, G3 pharmaceuticals, Ardelyx and Tricida; stock options from KBP Pharmaceuticals, sc Pharmaceuticals, Sarfez pharmaceuticals, Relypsa, Cereno scientific, SQinnovations, G3 pharmaceuticals, Ardelyx and Tricida; patent for site specific delivery of eplerenone to the myocardium US patent Number 9931412. N.G. reports honoraria from Novartis and Boehringer. All other authors have no conflicts to disclose.